The pharmacokinetics and pharmacodynamics of tandospirone in rats exposed to conditioned fear stress

European Neuropsychopharmacology

Volumn 16, Issue 5, 2006, Pages 376-382

  Nishitsuji, Kyoko ^a   To, Hideto ^b   Shimizu, Tokiko ^a   Yanase, Yuko ^a   Yamada, Tomomi ^a   Hara, Chiaki ^c   Mine, Kazunori ^a   Higuchi, Shun ^b  

^a KYUSHU UNIVERSITY   (Japan)

^b Hoshi University   (Japan)

^c DAIICHI UNIVERSITY OF PHARMACY   (Japan)

Author keywords

Brain concentration; Freezing behavior; Plasma level; Rat; Tandospirone

Indexed keywords

4 AMINOBUTYRIC ACID RECEPTOR; CHLORIDE CHANNEL; TANDOSPIRONE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BINDING AFFINITY; CONTROLLED STUDY; CORRELATION ANALYSIS; DRUG BLOOD LEVEL; DRUG BRAIN LEVEL; DRUG EFFECT; DRUG EFFICACY; DRUG POTENCY; FEAR; HIPPOCAMPUS; MALE; NONHUMAN; PRIORITY JOURNAL; RAT; RECEPTOR BINDING; STRESS; TRANQUILIZING ACTIVITY;

ANIMALS; ANTI-ANXIETY AGENTS; BRAIN; CONDITIONING (PSYCHOLOGY); FEAR; MALE; MOTOR ACTIVITY; PIPERAZINES; PYRIMIDINES; RATS; RATS, SPRAGUE-DAWLEY; STRESS, PSYCHOLOGICAL;

EID: 33744522330     PISSN: 0924977X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.euroneuro.2005.11.009     Document Type: Article

References (31)

1. Barradell L.B., and Fitton A. Tandospirone. CNS Drugs 5 (1996) 147-153
2. Blier P., Curet O., Chaput Y., and de Montigny C. Tandospirone and its metabolite, 1-(2-pyrimidinyl)-piperazine-II. Effects of acute administration of 1-PP and long-term administration of tandospirone on noradrenergic neurotransmission. Neuropharmacology 30 (1991) 691-701
3. Caccia S., Fong M.H., and Guiso G. Disposition of the psychotropic drugs buspirone, MJ-13805 and piribedil, and of their common active metabolite 1-(2-pyrimidinyl)-piperazine in the rat. Xenobiotica 15 (1985) 835-844
4. Cao B.J., and Rodgers R.J. Comparative behavioural profiles of buspirone and its metabolite 1-(2-pyrimidinyl)-piperazine (1-PP) in the murine elevated plus-maze. Neuropharmacology 36 (1997) 1089-1097
5. Chopin P., and Briley M. Animal models of anxiety : the effect of compounds that modify 5-HT neurotransmission. TIPS 8 (1987) 383-388
6. Christmas A.J., and Maxwell D.R. A comparison of the effects of some benzodiazepines and other drugs on aggressive and exploratory behavior in mice and rats. Neuropharmacology 9 (1970) 17-29
7. Conti L.H., Maciver C.R., Ferkany J.W., and Abreu M.E. Footshock-induced freezing behavior in rats as a model for assessing anxiolytics. Psychopharmacology 102 (1990) 492-497
8. Della Paschoa O.E., Kruk M.R., and Danhof M. Pharmacokinetic-pharmacodynamic modeling of behavioural responses. Neurosci. Biobehav. Rev. 23 (1998) 229-236
9. Erikkson E., and Humble M. Serotonin in psychiatric pathophysiology: a review of data from experimental and clinical research. In: Pohl R., and Gershon S. (Eds). Progress in Basic Clinical Pharmacology. The Biological Basis of Psychiatric Treatment vol. 3 (1990), Karger, Basel 66-119
10. Evans S.M., Troisi II J.R., and Griffiths R.R. Tandospirone and alprazolam: comparison of behavioral effects and abuse liability in humans. J. Pharmacol. Exp. Ther. 271 (1994) 683-694
11. Fanselow M.S., and Helmstetter F.J. Conditional analgesia, defensive freezing, and benzodiazepines. Behav. Neurosci. 102 (1988) 233-243
12. Feighner J.P., Merideth C.H., and Hendrickson G.A. A double-blind comparison of buspirone and diazepam in outpatients with generalized anxiety disorder. J. Clin. Psychiatry 43 (1982) 103-107
13. Hamik A., Oksenberg D., Fischette C., and Peroutka S.J. Analysis of tandospirone (SM-3997) interactions with neurotransmitter receptor binding sites. Biol. Psychiatry 28 (1990) 99-109
14. Handley S.L., and McBlane J.W. 5HT drugs in animal models of anxiety. Psychopharmacology 112 (1993) 13-20
15. Handley S.L., McBlane J.W., Critchley M.A.E., and Njung'e K. Multiple serotonin mechanisms in animal models of anxiety: environmental, emotional and cognitive factors. Behav. Brain Res. 58 (1993) 203-210
16. Hashimoto S., Inoue T., and Koyama T. Serotonin reuptake inhibitors reduce conditioned fear stress-induced freezing behavior in rats. Psychopharmacology 123 (1996) 182-186
17. Honma T., and Kitagawa S. Effects of minor tranquilizers and neuroleptics on open-field behavior in rats. Folia Pharm. Japon 73 (1977) 337-345 (English abstract)
18. Kalin N.H., Sherman J.E., and Takahashi L.K. Antagonism of endogenous CRH systems attenuates stress-induced freezing behavior in rats. Brain Res. 457 (1988) 130-135
19. Kidd E.J., Haj-Dahmane S., Jolas T., Lanfumey L., Fattaccini C.M., Guardiola-Lemaitre B., Gozlan H., and Hamon M. New methoxy-chroman derivatives, 4[N-(5-methoxy-chroman-3-yl)N-propylamino] butyl-8-azaspiro-(4,5)-decane-7,9-dione [(+/-)-S 20244] and its enantiomers, (+)-S 20499 and (-)-S 20500, with potent agonist properties at central 5-hydroxytryptamine1A receptors. J. Pharmacol. Exp. Ther. 264 (1993) 863-872
20. Maki Y., Inoue T., Izumi T., Muraki I., Ito K., Kitaichi Y., Li X., and Koyama T. Monoamine oxidase inhibitors reduce conditioned fear stress-induced freezing behavior in rats. Eur. J. Pharmacol. 406 (2000) 411-418
21. Miller L.G., Thompson M.L., Byrnes J.J., Greenblatt D.J., and Shemer A. Kinetics, brain uptake, and receptor binding of tandospirone and its metabolite 1-(2-pyrimidinyl)-piperazine. J. Clin. Psychopharmacol. 12 (1992) 341-345
22. Muraki I., Inoue T., Hashimoto S., Izumi T., Ito K., Ohmori T., and Koyama T. Effect of subchronic lithium carbonate treatment on anxiolytic-like effect of citalopram and MKC-242 in conditioned fear stress in the rat. Eur. J. Pharmacol. 383 (1999) 223-229
23. Nishitsuji K., To H., Murakami Y., Kodama K., Kobayashi D., Yamada T., Kubo C., and Mine K. Tandospirone in the treatment of generalized anxiety disorder and mixed anxiety-depression. Clin. Drug Invest 24 (2004) 121-126
24. 1A agonist, in three stress paradigms: immobilization, forced swim and conditioned fear. Brain Res. 580 (1992) 205-214
25. Sansone M. Influence of benzodiazepine tranquilizers on amphetamine-induced locomotor stimulation in mice. Psychopharmacology 71 (1980) 63-65
26. Shimizu H., Hirose A., Tatsuno T., Nakamura M., and Katsube J. Pharmacological properties of SM-3997: a new anxioselective anxiolytic candidate. Jpn. J. Pharmacol. 45 (1987) 493-500
27. Stahl S.M. Drug treatment for anxiety. Essential psychopharmacology: neuroscientific basis and practical applications. 2nd ed. (2000), Cambridge University Press, Cambridge 299-324
28. 1A receptor-related anxiolytics, on daytime sleepiness and psychomotor functions: a comparative double-blind study with diazepam. Jpn. J. Psychopharmacol. 13 (1993) 213-224
29. Tanaka H., Shimizu H., Kumasaka Y., Hirose A., Tatsuno T., and Nakamura M. Autoradiographic localization and pharmacological characterization of [3H] tandospirone binding sites in the rat brain. Brain Res. 546 (1991) 181-189
30. Tollefson G.D., Lancaster S.P., and Montague-Clouse J. The association of buspirone and its metabolite 1-pyrimidinylpiperazine in the remission of comorbid anxiety with depressive features and alcohol dependency. Psychopharmacol. Bull. 27 (1991) 163-170
31. Tsutsui S., Saito T., and Katsura T. Clinical evaluation of a new psychotropic drug, tandospirone (SM-3997) - long term treatment on psychosomatic disease and neurosis. Clin. Rep. 26 (1992) 410-421 (Japanese)